Circulating Tumor DNA-based Minimal Residual Disease Detection in Colorectal Cancer Management : Episode 13
Interpreting and Communicating ctDNA Results
The panel examines challenges in interpreting circulating tumor DNA results and their impact on clinical decision-making processes.
EP: 1.Overview of colorectal cancer and its management
EP: 2.Background on Colorectal Cancer Screening and its Role in Patient Care
EP: 3.Circulating Tumor DNA Detection Techniques
EP: 4.Describing the Value of ctDNA in Clinical Practice
EP: 5.Clinical study of ctDNA-based MRD detection and INTERCEPT program update
EP: 6.Recent findings from BESPOKE
EP: 7.Incorporating ctDNA-Based MRD Testing and Study Findings Into Clinical Practice
EP: 8.Key Considerations for Selection of ctDNA Detection Methods
EP: 9.Clinical Utility of ctDNA Testing
EP: 10.Barriers to Implementing ctDNA Testing
EP: 11.ctDNA Testing in a CRC Clinical Scenario
EP: 12.ctDNA to Inform Adjuvant Therapy and the CIRCULATE Trial
Now Viewing
EP: 13.Interpreting and Communicating ctDNA Results
EP: 14.Addressing Gaps in ctDNA Testing
EP: 15.Exploring the Future of ctDNA and Novel Treatment Strategies
- How do you factor ctDNA into treatment selection and management?
- How do you integrate ctDNA with radiographic or pathologic correlates?
- Are there challenges associated with the interpretation of ctDNA to inform your clinical decision-making?
- What do we know about sensitivity of ctDNA with different sites of metastatic disease?
- Navigating positive results
- Navigating false negatives
- How do you describe these test results to patients?
- Do you have any practical insights to share for interpretating and presenting results?
Recent Videos
Related Content
